In 2010, if you were diagnosed with Stage IV melanoma — the advanced form of the skin cancer that has spread to distant organs — your doctor would have given you a median survival estimate of six to nine months. Five years later, roughly 5 to 10% of patients were still alive. Those numbers were not pessimism; they were the clinical reality of a disease for which no effective systemic treatment existed. Then, within the span of a decade, a new class of cancer drugs fundamentally rewrote that story. Today, nearly half of patients with advanced melanoma treated with the best available combination immunotherapy are alive seven years later — and many of them have been off treatment for years. This is what happened, why it worked, and what it means if you or someone you love is dealing with melanoma now.
Before Immunotherapy: What Stage IV Melanoma Meant
Melanoma begins in melanocytes, the pigment-producing cells of the skin. It is far less common than basal cell or squamous cell skin cancers, but it is by far the most dangerous: it spreads quickly, travels to the lungs, liver, brain, and bone, and — once it had spread in the pre-immunotherapy era — was almost invariably fatal.
Chemotherapy, the cornerstone of most other cancer treatments, barely worked in melanoma. The standard regimen, dacarbazine, produced objective responses in about 15 to 20% of patients, but those responses were rarely durable. No chemotherapy drug was ever shown to extend overall survival in a randomized trial of advanced melanoma. The disease became known among oncologists as one of the most treatment-resistant cancers in existence.
Approximately 100,640 Americans are diagnosed with melanoma each year, and about 8,290 die of it, according to the National Cancer Institute. The majority of diagnoses are caught early — localized melanoma has a 5-year survival rate above 98% and is cured by surgery in most cases. But the subset that progresses to Stage IV was, until very recently, a group for whom medicine had remarkably little to offer.
That changed with two near-simultaneous breakthroughs in the early 2010s: the first checkpoint inhibitors, and the first targeted therapies for a specific genetic mutation found in about half of all melanomas.
The Checkpoint Inhibitor Breakthrough
The immune system is supposed to find and destroy cancer cells. In many cases it fails — not because it cannot recognize the cancer, but because the cancer has learned to apply a molecular “off switch” that tells immune cells to stand down. This is accomplished through a pathway involving proteins called PD-1 and CTLA-4, which normally function as brakes on immune activity to prevent the immune system from attacking healthy tissue. Melanoma cells — and many other cancers — exploit these same brakes to hide from immune surveillance.
Checkpoint inhibitors are drugs that remove those brakes. They do not target the cancer cell directly. Instead, they block the inhibitory signal, allowing T-cells to resume their attack on the tumor.
The first checkpoint inhibitor approved for melanoma was ipilimumab (Yervoy), which blocks CTLA-4. The FDA approved it in 2011 — the first drug ever shown to improve overall survival in advanced melanoma in a randomized trial. The responses were not universal, and the drug came with significant immune-related side effects, but for the first time, some patients with Stage IV melanoma were achieving durable remissions.
The second was nivolumab (Opdivo), which blocks PD-1. Approved in 2014, it produced higher response rates and a more favorable side-effect profile than ipilimumab. A third PD-1 inhibitor, pembrolizumab (Keytruda), was approved the same year and has since been shown in multiple trials to match nivolumab’s efficacy with similar tolerability.
The question that the CheckMate 067 trial was designed to answer was deceptively simple: was combining both approaches — blocking both CTLA-4 and PD-1 simultaneously — better than either alone?
CheckMate 067: The Trial That Changed Everything
CheckMate 067 (NCT01844505) was a global Phase 3 randomized controlled trial that enrolled 945 previously untreated patients with advanced (Stage III or IV) melanoma at sites across the United States, Europe, Australia, and Asia. Patients were randomly assigned to one of three arms: nivolumab plus ipilimumab (the combination), nivolumab alone, or ipilimumab alone.
Ipilimumab was the control arm because, at the time the trial was designed, it was the established standard of care — the only drug ever shown to extend survival in advanced melanoma. That historical context matters: the trial was measuring improvement over what was then considered the best available option.
The results were first published in 2015 and showed remarkable efficacy for the combination arm. But the real significance of the trial only became clear with long-term follow-up. A 5-year analysis, a subsequent 6.5-year analysis, and then a definitive 7-year follow-up published in the New England Journal of Medicine in June 2022 delivered data that would have been considered impossible a decade earlier.
The trial was led by Jedd Wolchok, then at Memorial Sloan Kettering Cancer Center in New York, alongside Vanna Chiarion-Sileni in Italy and Reinaldo Gonzalez in the United States, with international co-investigators.
Seven Years Later: The Numbers
At the 7-year mark, across all 945 patients enrolled, the results were as follows:
In the nivolumab plus ipilimumab arm: 43% of patients were alive. Not in partial remission, not on treatment — alive and accounted for, seven years after a Stage IV melanoma diagnosis that would previously have carried a median survival under one year.
In the nivolumab alone arm: 37% were alive at seven years.
In the ipilimumab alone arm (the former standard of care): 19% were alive at seven years.
Median overall survival in the combination arm was 72.1 months — approximately six years. This is the median: half of patients in the combination arm survived more than six years. Median overall survival for nivolumab alone was 36.9 months. For ipilimumab alone, it was 19.9 months. To put this in historical perspective: the median survival for Stage IV melanoma with dacarbazine chemotherapy, the pre-immunotherapy standard, was approximately 6 to 9 months.
The hazard ratio for death comparing combination therapy to ipilimumab alone was 0.52 — meaning patients on the combination had a 48% lower risk of dying at any given point. This figure held up across nearly all analyzed subgroups.
On safety, the combination comes at a meaningful cost. Grade 3 or 4 immune-related adverse events occurred in 59% of patients on the combination versus 21% with nivolumab alone and 28% with ipilimumab alone. These can include colitis, hepatitis, endocrine dysfunction (thyroiditis, hypophysitis), pneumonitis, and other inflammatory conditions. They are serious and require management with corticosteroids and, in some cases, other immunosuppressive agents. They are also, in most cases, manageable — and they did not prevent the survival benefit from materializing. The side effect burden is one of the reasons why some patients receive nivolumab alone rather than the combination; in patients unlikely to tolerate the more intensive regimen, nivolumab monotherapy with its 37% 7-year survival still represents a profound improvement over any historical standard.
Why the Responses Last
One of the most striking — and scientifically important — features of checkpoint inhibitor responses in melanoma is their durability. In traditional oncology, when a drug stops being given, the cancer typically resumes growing. With immunotherapy, the opposite is often observed: patients who respond and complete their treatment course frequently maintain their response for years after stopping.
In CheckMate 067, a notable proportion of patients on the combination arm had discontinued treatment well before the 7-year analysis (many stopped after 2 years, per protocol) yet remained alive and disease-free. This pattern suggests that successful immunotherapy doesn’t just suppress the cancer while the drug is present — it reprograms the immune system’s memory, leaving behind a persistent population of T-cells trained to recognize and destroy the cancer if it reappears.
This has transformed how oncologists discuss prognosis with patients. A patient who achieves a complete response to combination immunotherapy and has been off treatment for three years is not in the same category as someone who achieved a temporary chemotherapy response. The immune memory is durable in a way that drug efficacy typically is not.
Long-term remission and functional cure are now realistic goals for a subset of patients with Stage IV melanoma. That sentence would not have been meaningful to write before 2011.
BRAF Mutations: A Second Weapon
Immunotherapy is not the only revolution in melanoma treatment. Around the same time that checkpoint inhibitors arrived, researchers identified that approximately 50% of melanomas carry a mutation in a gene called BRAF — most commonly a specific change called BRAF V600E or V600K. This mutation functions like a permanently stuck accelerator, driving uncontrolled cell division.
Two targeted drugs — dabrafenib (targeting BRAF directly) and trametinib (targeting a downstream protein called MEK) — were developed to block this pathway, and their combination was FDA-approved for BRAF-mutant advanced melanoma. The combination produces response rates around 65%, with rapid tumor shrinkage that can begin within days. For patients who need fast responses — for example, because rapidly growing brain metastases require urgent treatment — BRAF/MEK-targeted therapy can provide critical short-term disease control.
The limitation of BRAF/MEK therapy is resistance: the cancer often finds alternative pathways to grow around the blockade, and most patients who respond eventually progress. Immunotherapy, by contrast, works more slowly but achieves responses that can last indefinitely. This has prompted significant clinical interest in sequencing or combining the two approaches, and trials exploring those questions are ongoing.
If you or a family member has been diagnosed with melanoma, knowing BRAF status is essential. All patients with metastatic melanoma should have their tumor tested for BRAF mutations at diagnosis. It determines eligibility for targeted therapy and helps guide the treatment sequence discussion with your oncologist.
Melanoma Survival Rates by Stage, Explained
Melanoma survival rates have improved significantly across all stages, but they vary dramatically depending on when the disease is diagnosed. The following figures reflect current NCI SEER data and incorporate the impact of the immunotherapy era on metastatic disease.
Localized melanoma (Stage I–II, confined to the skin) carries a 5-year relative survival rate of approximately 98–99%. Surgery is the primary treatment, and cure is the realistic expectation in most cases. Early detection through regular skin checks and prompt attention to changing moles is the most effective intervention available for this disease.
Regional melanoma (Stage III, spread to nearby lymph nodes) has a 5-year relative survival of approximately 65–70%. Adjuvant (post-surgery) immunotherapy with pembrolizumab or nivolumab has been shown to reduce the risk of recurrence significantly in this setting, and is now standard of care for most Stage III patients. Long-term follow-up data from adjuvant trials show that these benefits persist for years.
Distant-stage melanoma (Stage IV, spread to distant organs) has a current SEER 5-year relative survival of approximately 31% — a figure that is itself an artifact of the immunotherapy era, since it blends data from before and after the checkpoint inhibitor revolution. In patients treated with modern combination immunotherapy, the 7-year survival data from CheckMate 067 suggest that the realistic long-term survival estimate for patients who start first-line combination therapy is now substantially higher than any published SEER figure currently reflects, given the lag in population data catching up to clinical reality.
The key practical point: the SEER statistics for Stage IV melanoma underestimate what is currently achievable with modern treatment. If you are diagnosed with advanced melanoma today and treated at a center experienced with immunotherapy, your individual outlook is better than historical averages suggest.
What This Means for Patients Today
For anyone navigating a melanoma diagnosis — whether a primary tumor on the skin, a suspicious lymph node, or an advanced metastatic diagnosis — several concrete points follow from the evidence reviewed above.
- Check every skin lesion with a dermatologist promptly. The single most effective thing the melanoma story teaches is this: localized disease is almost universally curable with surgery. A melanoma that is caught and removed before it spreads carries an excellent prognosis. The same disease diagnosed at Stage IV represents a fundamentally different clinical challenge, even with modern immunotherapy. Annual full-body skin exams with a dermatologist, and self-examination for the ABCDEs of melanoma (Asymmetry, Border irregularity, Color variation, Diameter over 6mm, Evolution), save lives in ways that no drug can match.
- Demand BRAF mutation testing at diagnosis of metastatic disease. This is now standard of care, but confirm it has been ordered. Knowing your BRAF status shapes the entire treatment discussion. BRAF-mutant and BRAF-wildtype metastatic melanoma may call for different first-line approaches depending on urgency, disease burden, and your clinical situation.
- Ask specifically about combination immunotherapy eligibility. The combination of nivolumab plus ipilimumab is FDA-approved for unresectable or metastatic melanoma and offers the highest 7-year survival rates seen in any advanced solid tumor in the immunotherapy era. However, it also carries significant immune-related toxicity risk. Whether the combination is appropriate for you depends on your performance status, organ function, autoimmune history, and tolerance for intensive monitoring. Have this conversation explicitly with your oncologist — not all patients are offered the combination by default.
- Seek care at a melanoma center of excellence. Immune-related adverse events from checkpoint inhibitors require experienced management. Endocrine toxicities, colitis, and other complications can occur weeks or months after treatment begins. Centers that manage high volumes of immunotherapy-treated patients have developed protocols that detect and treat these complications more effectively. For advanced melanoma especially, where treatment intensity and side effect management are central to outcomes, the treating institution matters.
- Ask about clinical trial eligibility. The pace of progress in melanoma has been rapid, and trials testing new combinations, sequences, and earlier-stage applications are actively recruiting. CancerInsight’s clinical trial search tool and ClinicalTrials.gov can help you identify studies near you. Enrolment in a trial is how the next generation of melanoma treatment improvements gets built.
- For Stage III: ask about adjuvant immunotherapy. The KEYNOTE-716 and CheckMate 76K trials have established that pembrolizumab and nivolumab, respectively, reduce the risk of recurrence in surgically resected Stage IIB/IIC and Stage III melanoma. If you or a family member has had a melanoma surgically removed and was told the lymph nodes are involved or the primary tumor is high-risk, ask whether adjuvant immunotherapy was discussed in your care plan.
What Comes Next
Melanoma remains an active research frontier despite the advances of the past decade. Several directions are generating significant excitement:
Personalized mRNA cancer vaccines. Moderna and Merck, building on the same mRNA platform used in COVID-19 vaccines, are developing individualized melanoma vaccines (mRNA-4157/V940) tailored to each patient’s specific tumor mutation profile. Early-phase trials combining the vaccine with pembrolizumab showed significantly reduced recurrence risk compared with pembrolizumab alone in Stage III/IV melanoma. Phase 3 trials are underway. If those results hold, personalized vaccines could become a routine component of melanoma adjuvant therapy within the next few years.
Tumor-infiltrating lymphocyte (TIL) therapy. Lifileucel (Amtagvi), a therapy that harvests tumor-infiltrating lymphocytes from a patient’s own melanoma, expands them in the laboratory, and reinfuses them, was FDA-approved in February 2024 for advanced melanoma that has progressed after other treatments. This represents a new category of cellular therapy for solid tumors — separate from CAR-T, and drawing on the immune cells already present and trained within the tumor itself.
Earlier intervention. The adjuvant trials (KEYNOTE-716, CheckMate 76K) are steadily moving immunotherapy into earlier stages of disease, where the immune system has more to work with and treatment is more likely to be curative. The question of whether immunotherapy could eventually replace surgery as the primary intervention for some melanomas remains aspirational, but it is no longer scientifically implausible given the responses seen in neoadjuvant trials.
The melanoma story is — alongside lung cancer immunotherapy and certain blood cancers — one of the defining success stories of modern oncology. A disease that was nearly uniformly fatal once it spread is now one where long-term survival is realistic for a significant proportion of patients, and where the mechanisms driving further improvement are already in clinical development. For patients diagnosed with melanoma today, the evidence base behind this progress is not a reason for complacency — early detection, expert care, and prompt treatment remain essential. But it is a legitimate reason for hope in a way that would not have been scientifically supportable fifteen years ago.